Ginkgo Bioworks DNA Change in Deferred Revenue
Change in Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Ginkgo Bioworks in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInContractWithCustomerLiability.
The official record: Ginkgo Bioworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ginkgo Bioworks's change in deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ginkgo Bioworks's change in deferred revenue?
- Ginkgo Bioworks (DNA) reported change in deferred revenue of -$2.61M in Q1 2026.
- How has Ginkgo Bioworks's change in deferred revenue changed year-over-year?
- Ginkgo Bioworks's change in deferred revenue increased by 80.2% year-over-year, from -$13.19M to -$2.61M.
- What is the long-term trend for Ginkgo Bioworks's change in deferred revenue?
- Over 4 years (2021 to 2025), Ginkgo Bioworks's change in deferred revenue has grown at a 30.9% compound annual growth rate (CAGR), from -$11.03M to -$32.39M.
- What does change in deferred revenue mean?
- Change in payments received from customers for goods/services not yet delivered — a key SaaS and subscription metric.